GlassScriptPhysician profile
Kinjal Dargan
NPI 1346683224
$882.49
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2021: $41.13 · 2023: $72.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $165.94 | 2019 | |
| Celgene Corporation | $140.86 | 2019 | |
| Pfizer INC. | $84.54 | 2019 | |
| Eisai INC. | $69.78 | 2019-2023 | |
| Genentech USA, INC. | $59.76 | 2019 | |
| Lilly USA, LLC | $43.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $42.05 | 2019 | |
| Tesaro, INC. | $35.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.65 | 2019 | |
| Incyte Corporation | $27.43 | 2019 | |
| Seagen INC. | $27.13 | 2019 | |
| Abbvie INC. | $25.58 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.59 | 2019 | |
| Merck Sharp & Dohme LLC | $19.25 | 2023 | Lynparza, Welireg, Keytruda |
| Foundation Medicine, INC. | $18.71 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $18.36 | 2019 | |
| Taiho Oncology, INC. | $17.75 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $15.55 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinjal Dargan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.